The Food and Drug Administration said Tuesday that a review of popular painkillers found naproxen sold by Bayer AG under the brand name Aleve may carry a lower cardiac risk than rival drugs The evidence comes from a range of clinical studies the agency has evaluated since  when the heart risks of a class of leading painkillers became an issue of widespread public concern At the time the agency looked at the evidence and concluded that the data did not permit rank ordering of the drugs with regard to cardiovascular
  